Literature DB >> 2794507

Distinct roles of IL-1 and IL-6 in human T cell activation.

F A Houssiau1, P G Coulie, J Van Snick.   

Abstract

We have examined the mechanisms underlying the activation of human T cells by IL-1 and IL-6. We report that PHA-stimulated accessory cell-depleted tonsillar T cells fractionated on the basis of their density show a high degree of heterogeneity in their proliferative response to these cytokines, inasmuch as small dense lymphocytes essentially fail to respond whereas large cells proliferate extensively. This differential response could be ascribed to the fact that only the large cells produced IL-2 under these circumstances, thus providing unequivocal evidence for the existence of an IL-2-mediated step in the activation of human T cells by IL-1 and IL-6. The synergy between IL-1 and IL-6 was found to result from their complementary effects on the production of and response to IL-2, with IL-1 playing a preponderant role in the induction of IL-2, and IL-6 being required, in addition to IL-1, for optimal IL-2-responsiveness. Using small tonsillar T cells, it was possible to show that, concomitant with the enhanced response to IL-2, IL-6 induced a marked increase in cell size and in protein synthesis. In the absence of other factors, this activation was not followed by entry into S phase, suggesting that the essential role of IL-6 in T cell activation is to induce the cells to move from G0 to G1, where they become more responsive to the small amounts of IL-2 induced by IL-1.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2794507

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  IL-6 enhances the generation of cytolytic T lymphocytes in the allogeneic mixed leucocyte reaction.

Authors:  J E Ming; R M Steinman; A Granelli-Piperno
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

2.  Chlamydia trachomatis pneumonia induces in vivo production of interleukin-1 and -6.

Authors:  D M Magee; J G Smith; C A Bleicker; C J Carter; L F Bonewald; J Schachter; D M Williams
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

Review 3.  Biocompatibility of implants: lymphocyte/macrophage interactions.

Authors:  James M Anderson; Amy K McNally
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

Review 4.  Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis.

Authors:  Gianfranco Ferraccioli; Luisa Bracci-Laudiero; Stefano Alivernini; Elisa Gremese; Barbara Tolusso; Fabrizio De Benedetti
Journal:  Mol Med       Date:  2010-08-02       Impact factor: 6.354

5.  Response of serum cytokines in patients undergoing laparoscopic cholecystectomy.

Authors:  J M Cho; A J LaPorta; J R Clark; M J Schofield; S L Hammond; P L Mallory
Journal:  Surg Endosc       Date:  1994-12       Impact factor: 4.584

6.  Lymphocyte/macrophage interactions: biomaterial surface-dependent cytokine, chemokine, and matrix protein production.

Authors:  David T Chang; Jacqueline A Jones; Howard Meyerson; Erica Colton; Il Keun Kwon; Takehisa Matsuda; James M Anderson
Journal:  J Biomed Mater Res A       Date:  2008-12-01       Impact factor: 4.396

7.  Expression of interleukin-6 receptor on blood lymphocytes without in vitro activation.

Authors:  H Zola; L Flego
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

Review 8.  Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense.

Authors:  L Graeve; M Baumann; P C Heinrich
Journal:  Clin Investig       Date:  1993-08

9.  In vitro interleukin-1 (IL-1) production in thymic hyperplasia and thymoma from patients with myasthenia gravis.

Authors:  C Aime; S Cohen-Kaminsky; S Berrih-Aknin
Journal:  J Clin Immunol       Date:  1991-09       Impact factor: 8.317

10.  Infusions of interleukin-1 alpha after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity.

Authors:  E Katsanis; D J Weisdorf; Z Xu; B B Dancisak; M L Halet; B R Blazar
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.